fda compounding semaglutide news Compound versions of GLP-1 drugs for weight loss halted by HEALTH NEWS ALERT * FDA

Neuroscience 405, 5567

Almost 37% of those on semaglutide showed less liver scarring, compared to nearly 23% in the placebo group

Less common: abdominal pain, rash, drowsiness, fatigue, flatulence, itching, Stevens-Johnson syndrome, urinary retention, hives, vomiting, dry mouth

Boatright KM et al (2003) A unified model for apical caspase activation

Several randomized, clinical studies have found that GLP-1 receptor agonists like liraglutide and semaglutide significantly suppress appetite and reduce hunger sensations compared with placebo

Shopify Merchants Can Officially Sell Via ChatGPT As of March 24th, all brands powered by Shopify can now sell directly to U.S shoppers on ChatGPT